Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.

@article{Fuchs2011PostoperativeAC,
  title={Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.},
  author={Charles S. Fuchs and Joel E Tepper and Donna Niedzwiecki and Donna R Hollis and Harvey J. Mamon and Richard S. Swanson and Daniel G. Haller and Tomislav Dragovich and Steven Robert Alberts and G A Georg Bjarnason and Christopher G Willett and Peter C. Enzinger and Richard M. Goldberg and Alan Paul Venook and Robert J. Mayer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4003}
}
4003 Background: Following curative resection of gastric or GEJ adenocarcinoma, INT-0116 demonstrated superior survival for pts who received postoperative bolus 5-FU and leucovorin (LV) before and after concomitant 5-FU and RT compared to surgery alone. We assessed whether a postoperative chemoRT regimen that replaces 5-FU/LV with a potentially more active systemic therapy (ECF) improves overall survival (OS). METHODS Patients with resected gastric or GEJ adenocarcinoma were randomly assigned… CONTINUE READING
36 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…